Our Pipeline

Our determination to find answers for patients and their families motivates us to pursue medicines and vaccines with the greatest potential to improve lives and protect public health. With a strong focus on difficult-to-treat diseases and immunization, our R&D pipeline includes 79 clinical-stage projects, 23 of which are in phase 3 or have been submitted to regulatory authorities for approval. Some of these are new molecular entities while others are existing products with potential new indications, or different formulations. All of them are made possible by people who volunteer to participate in a clinical trial.

Phase 1
24
Phase 2
32
Phase 3
22
Registration
1

Search for a specific a clinical-stage projects

All therapeutic areas
All phases
All expected timeline
79 project(s) of 79
Therapeutic Area
Phase
Name
Description
Indication

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR441566

Phase

1
2
3
R

Description

TNFR1 signaling inhibitor

Indication

Psoriasis

Psoriasis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR443765

Phase

1
2
3
R

Description

Anti-IL-13/TSLP NANOBODY® VHH

Indication

Asthma

Asthma

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR444336

Phase

1
2
3
R

Description

Non-beta IL-2 SYNTHORIN™

Indication

Inflammatory indication

Inflammatory indication

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR444559

Phase

1
2
3
R

Description

Anti-CD38 mAb Next Generation

Indication

Inflammatory indication

Inflammatory indication

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR445399

Phase

1
2
3
R

Description

Anti-IL1R3 mAb
New

Indication

Inflammatory indication

New

Inflammatory indication

New

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR445611

Phase

1
2
3
R

Description

Anti-CX3CR1 NANOBODY® VHH
New

Indication

Inflammatory indication

New

Inflammatory indication

New

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

Anti-OX40L mAb

Indication

Asthma

Asthma

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

Anti-OX40L mAb

Indication

Atopic Dermatitis

Atopic Dermatitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent®

Phase

1
2
3
R

Description

Anti-IL-4/IL-13 mAb

Indication

Ulcerative Colitis

Ulcerative Colitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

eclitasertib

Phase

1
2
3
R

Description

RIPK1 inhibitor

Indication

Ulcerative Colitis

Ulcerative Colitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

Anti-CD40L mAb

Indication

Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

Anti-CD40L mAb

Indication

Sjögren‘s Syndrome

Sjögren‘s Syndrome

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Kevzara®

Phase

1
2
3
R

Description

Anti-IL-6 mAb

Indication

Systemic juvenile arthritis

Systemic juvenile arthritis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Kevzara®

Phase

1
2
3
R

Description

Anti-IL-6 mAb

Indication

Polyarticular juvenile idiopathic arthritis

Polyarticular juvenile idiopathic arthritis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Chronic spontaneous urticaria

Chronic spontaneous urticaria

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Asthma

Asthma

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

IgG4-related disease

IgG4-related disease

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR442970

Phase

1
2
3
R

Description

Anti-TNFa/OX40L NANOBODY® VHH
New phase

Indication

Hidradenitis Suppurativa

New phase

Hidradenitis Suppurativa

New phase

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR444656

Phase

1
2
3
R

Description

IRAK4 degrader
New phase

Indication

Hidradenitis Suppurativa

New phase

Hidradenitis Suppurativa

New phase

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR444656

Phase

1
2
3
R

Description

IRAK4 degrader
New phase

Indication

Atopic dermatitis

New phase

Atopic dermatitis

New phase

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR445088

Phase

1
2
3
R

Description

Complement C1s inhibitor

Indication

Antibody-mediated rejection

Antibody-mediated rejection

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent®

Phase

1
2
3
R

Description

Anti-IL-4/IL-13 mAb

Indication

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent®

Phase

1
2
3
R

Description

Anti-IL-4/IL-13 mAb

Indication

Bullous pemphigoid

Bullous pemphigoid

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent®

Phase

1
2
3
R

Description

Anti-IL-4/IL-13 mAb

Indication

Chronic pruritis of unknown origin

Chronic pruritis of unknown origin

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

itepekimab

Phase

1
2
3
R

Description

Anti-IL-33 mAb

Indication

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

TZIELD™

Phase

1
2
3
R

Description

Anti-CD3 mAb
New

Indication

Type 1 Diabetes

New

Type 1 Diabetes

New

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent®

Phase

1
2
3
R

Description

Anti-IL-4/IL-13 mAb

Indication

Chronic spontaneous urticaria

Chronic spontaneous urticaria

Therapeutic Area

Neurology

1
2
3
R

Name

SAR446159

Phase

1
2
3
R

Description

Anti-Synuclein/IGF1R mAb

Indication

Parkinson's disease

Parkinson's disease

Therapeutic Area

Neurology

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

Anti-CD40L mAb

Indication

Multiple sclerosis

Multiple sclerosis

Therapeutic Area

Neurology

1
2
3
R

Name

SAR443820

Phase

1
2
3
R

Description

RIPK1 inhibitor

Indication

Multiple sclerosis

Multiple sclerosis

Therapeutic Area

Neurology

1
2
3
R

Name

SAR443820

Phase

1
2
3
R

Description

RIPK1 inhibitor

Indication

Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

Therapeutic Area

Neurology

1
2
3
R

Name

SAR445088

Phase

1
2
3
R

Description

Complement C1s inhibitor

Indication

Chronic inflammatory demyelinating polyneuropathy

Chronic inflammatory demyelinating polyneuropathy

Therapeutic Area

Neurology

1
2
3
R

Name

tolebrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Secondary Progressive MS

Secondary Progressive MS

Therapeutic Area

Neurology

1
2
3
R

Name

tolebrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Primary Progressive MS

Primary Progressive MS

Therapeutic Area

Neurology

1
2
3
R

Name

tolebrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

Therapeutic Area

Oncology

1
2
3
R

Name

pegenzileukin

Phase

1
2
3
R

Description

Non-alpha IL-2 SYNTHORIN™

Indication

Solid tumors (dose optimization)

Solid tumors (dose optimization)

Therapeutic Area

Oncology

1
2
3
R

Name

SAR442257

Phase

1
2
3
R

Description

CD38/CD28/CD3 T-Cell engager

Indication

Multiple myeloma / Non-Hodgkin lymphoma

Multiple myeloma / Non-Hodgkin lymphoma

Therapeutic Area

Oncology

1
2
3
R

Name

SAR443216

Phase

1
2
3
R

Description

CD3/CD28/HER2 T-Cell engager

Indication

Gastric cancer

Gastric cancer

Therapeutic Area

Oncology

1
2
3
R

Name

SAR443579

Phase

1
2
3
R

Description

Trifunctional anti-CD123 NK-Cell engager

Indication

Acute Myeloid Leukemia

Acute Myeloid Leukemia

Therapeutic Area

Oncology

1
2
3
R

Name

SAR444200

Phase

1
2
3
R

Description

Anti-GPC3/TCR NANOBODY® VHH

Indication

Solid tumors

Solid tumors

Therapeutic Area

Oncology

1
2
3
R

Name

SAR444881

Phase

1
2
3
R

Description

Anti-ILT2 mAb

Indication

Solid tumors

Solid tumors

Therapeutic Area

Oncology

1
2
3
R

Name

SAR445419

Phase

1
2
3
R

Description

NK-Cell-based immunotherapy

Indication

Acute Myeloid Leukemia

Acute Myeloid Leukemia

Therapeutic Area

Oncology

1
2
3
R

Name

SAR445514

Phase

1
2
3
R

Description

Trifunctional anti-BCMA NK-Cell engager

Indication

Relapsed, Refractory Multiple Myeloma

Relapsed, Refractory Multiple Myeloma

Therapeutic Area

Oncology

1
2
3
R

Name

SAR445710

Phase

1
2
3
R

Description

Anti-PDL1/IL-15 fusion protein

Indication

Solid tumors

Solid tumors

Therapeutic Area

Oncology

1
2
3
R

Name

SAR445877

Phase

1
2
3
R

Description

Anti PD1/IL-15 fusion protein

Indication

Solid tumors

Solid tumors

Therapeutic Area

Oncology

1
2
3
R

Name

SAR446309

Phase

1
2
3
R

Description

HER2 T-Cell engager

Indication

Solid tumors

Solid tumors

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa®

Phase

1
2
3
R

Description

Anti-CD38 mAb

Indication

1-2L AML / acute lymphoblastic leukemia pediatrics

1-2L AML / acute lymphoblastic leukemia pediatrics

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa®

Phase

1
2
3
R

Description

Anti-CD38 mAb + combinations

Indication

Relapsed, Refractory Multiple Myeloma

Relapsed, Refractory Multiple Myeloma

Therapeutic Area

Oncology

1
2
3
R

Name

tusamitamab ravtansine

Phase

1
2
3
R

Description

Anti-CEACAM5 ADC + ramucirumab

Indication

Gastric cancer

Gastric cancer

Therapeutic Area

Oncology

1
2
3
R

Name

tusamitamab ravtansine

Phase

1
2
3
R

Description

Anti-CEACAM5 ADC

Indication

Exploratory solid tumors

Exploratory solid tumors

Therapeutic Area

Oncology

1
2
3
R

Name

tusamitamab ravtansine

Phase

1
2
3
R

Description

Anti-CEACAM5 ADC + ramucirumab

Indication

Non-small-cell lung cancer 2/3L

Non-small-cell lung cancer 2/3L

Therapeutic Area

Oncology

1
2
3
R

Name

tusamitamab ravtansine

Phase

1
2
3
R

Description

Anti-CEACAM5 ADC + pembrolizumab

Indication

1L Non-small-cell lung cancer

1L Non-small-cell lung cancer

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa®

Phase

1
2
3
R

Description

Anti-CD38 mAb SubQ + combinations

Indication

2/3L Relapsed, Refractory Multiple Myeloma

2/3L Relapsed, Refractory Multiple Myeloma

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa®

Phase

1
2
3
R

Description

Anti-CD38 mAb + combinations

Indication

Smoldering multiple myeloma

Smoldering multiple myeloma

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa®

Phase

1
2
3
R

Description

Anti-CD38 mAb + combinations

Indication

1L newly diagnosed multiple myeloma Te

1L newly diagnosed multiple myeloma Te

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa®

Phase

1
2
3
R

Description

Anti-CD38 mAb + combinations

Indication

1L newly diagnosed multiple myeloma Ti

1L newly diagnosed multiple myeloma Ti

Therapeutic Area

Oncology

1
2
3
R

Name

tusamitamab ravtansine

Phase

1
2
3
R

Description

Anti-CEACAM5 ADC

Indication

2/3L Non-small cell lung cancer

2/3L Non-small cell lung cancer

Therapeutic Area

Rare Blood Disorders

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Warm Autoimmune Hemolytic Anemia

Warm Autoimmune Hemolytic Anemia

Therapeutic Area

Rare Blood Disorders

1
2
3
R

Name

SAR445088

Phase

1
2
3
R

Description

Complement C1s inhibitor

Indication

Cold Agglutinin Disease

Cold Agglutinin Disease

Therapeutic Area

Rare Blood Disorders

1
2
3
R

Name

fitusiran

Phase

1
2
3
R

Description

RNAi targeting anti-thrombin

Indication

Hemophilia A and B pediatric

Hemophilia A and B pediatric

Therapeutic Area

Rare Blood Disorders

1
2
3
R

Name

fitusiran

Phase

1
2
3
R

Description

RNAi targeting anti-thrombin

Indication

Hemophilia A and B

Hemophilia A and B

Therapeutic Area

Rare Blood Disorders

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Immune Thrombocytopenia

Immune Thrombocytopenia

Therapeutic Area

Rare Diseases

1
2
3
R

Name

SAR439459

Phase

1
2
3
R

Description

Anti-TGFb mAb

Indication

Osteogenesis Imperfecta

Osteogenesis Imperfecta

Therapeutic Area

Rare Diseases

1
2
3
R

Name

SAR442501

Phase

1
2
3
R

Description

Anti-FGFR3 antibody

Indication

Achondroplasia

Achondroplasia

Therapeutic Area

Rare Diseases

1
2
3
R

Name

SAR443809

Phase

1
2
3
R

Description

Anti-Factor Bb mAb

Indication

Rare renal diseases

Rare renal diseases

Therapeutic Area

Rare Diseases

1
2
3
R

Name

SAR444836

Phase

1
2
3
R

Description

PAH replacement AAV-based gene therapy
New

Indication

Phenylketonuria

New

Phenylketonuria

New

Therapeutic Area

Rare Diseases

1
2
3
R

Name

Nexviazyme®

Phase

1
2
3
R

Description

Enzyme replacement therapy (GAA)

Indication

Pompe disease, infantile onset

Pompe disease, infantile onset

Therapeutic Area

Rare Diseases

1
2
3
R

Name

venglustat

Phase

1
2
3
R

Description

Oral GCS inhibitor

Indication

Fabry disease

Fabry disease

Therapeutic Area

Rare Diseases

1
2
3
R

Name

venglustat

Phase

1
2
3
R

Description

Oral GCS inhibitor

Indication

GM2 Gangliosidosis

GM2 Gangliosidosis

Therapeutic Area

Rare Diseases

1
2
3
R

Name

venglustat

Phase

1
2
3
R

Description

Oral GCS inhibitor

Indication

Gaucher disease type 3

Gaucher disease type 3

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0256

Phase

1
2
3
R

Description

mRNA RSV

Indication

RSV older adults

RSV older adults

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0273

Phase

1
2
3
R

Description

mRNA QIV

Indication

Influenza

Influenza

Therapeutic Area

Vaccines

1
2
3
R

Name

Fluzone® HD

Phase

1
2
3
R

Description

Inactivated influenza vaccine

Indication

Pediatric Influenza

Pediatric Influenza

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0125

Phase

1
2
3
R

Description

Live attenuated virus vaccine

Indication

Respiratory syncytial virus (toddler)

Respiratory syncytial virus (toddler)

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0202

Phase

1
2
3
R

Description

Next generation conjugate vaccine

Indication

Pneumococcal infection

Pneumococcal infection

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0218

Phase

1
2
3
R

Description

Vero cell Vaccine

Indication

Yellow Fever

Yellow Fever

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0230

Phase

1
2
3
R

Description

Multicomponent vaccine

Indication

Meningitis B

Meningitis B

Therapeutic Area

Vaccines

1
2
3
R

Name

MenQuadfi™

Phase

1
2
3
R

Description

Meningococcal (A,C,Y,W) conjugate vaccine

Indication

Meningitis, 6 weeks+ (USA / EU)

Meningitis, 6 weeks+ (USA / EU)

Therapeutic Area

Vaccines

1
2
3
R

Name

VRVg

Phase

1
2
3
R

Description

Purified Vero rabies vaccine

Indication

Rabies

Rabies

Program Updates

The following changes occurred in our R&D programs.

Updated on October 27, 2023

Therapeutic Area
Phase
Name
Description
Additional Details

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR445399

Phase

1
2
3
R

Description

Anti-IL1R3 mAb Indication: Inflammatory indication

Additional Details

See our quarterly earnings press release, issued on Oct 27, 2023

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR445611

Phase

1
2
3
R

Description

Anti-CX3CR1 NANOBODY® VHH Indication: Inflammatory indication

Additional Details

See our quarterly earnings press release, issued on Oct 27, 2023

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

eclitasertib

Phase

1
2
3
R

Description

RIPK1 inhibitor Indication: Cutaneous Lupus Erythematosus

Additional Details

See our quarterly earnings press release, issued on Oct 27, 2023

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor Indication: Atopic Dermatitis

Additional Details

See our quarterly earnings press release, issued on Oct 27, 2023

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR442970

Phase

1
2
3
R

Description

Anti-TNFa/OX40L NANOBODY® VHH Indication: Hidradenitis Suppurativa

Additional Details

See our quarterly earnings press release, issued on Oct 27, 2023

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR444656

Phase

1
2
3
R

Description

IRAK4 degrader Indication: Hidradenitis Suppurativa

Additional Details

See our quarterly earnings press release, issued on Oct 27, 2023

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR444656

Phase

1
2
3
R

Description

IRAK4 degrader Indication: Atopic dermatitis

Additional Details

See our quarterly earnings press release, issued on Oct 27, 2023

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

TZIELD™

Phase

1
2
3
R

Description

Anti-CD3 mAb Indication: Type 1 Diabetes

Additional Details

See our quarterly earnings press release, issued on Oct 27, 2023

Therapeutic Area

Oncology

1
2
3
R

Name

alomfilimab

Phase

1
2
3
R

Description

Anti-ICOS mAb Indication: Solid tumors

Additional Details

See our quarterly earnings press release, issued on Oct 27, 2023

Therapeutic Area

Rare Diseases

1
2
3
R

Name

SAR444836

Phase

1
2
3
R

Description

PAH replacement AAV-based gene therapy Indication: Phenylketonuria

Additional Details

See our quarterly earnings press release, issued on Oct 27, 2023

Therapeutic Area

Vaccines

1
2
3
R

Name

Beyfortus®

Phase

1
2
3
R

Description

Anti-RSV mAb Indication: Respiratory syncytial virus

Additional Details

See our quarterly earnings press release, issued on Oct 27, 2023

Related Links

Research & Development

See more

Technology Platforms

See more

Clinical trials & results

See more